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Edited by Veli-Pekka LehtoAbstract Angiogenin enhances tumorigenesis. However, the
mechanisms of angiogenin-induced angiogenesis and cancer cell
proliferation remain elusive. In this study, follistatin was identi-
ﬁed as a binding partner of angiogenin by a yeast two-hybrid
screen and conﬁrmed by a pull-down experiment. The interaction
of ﬂuorescently tagged angiogenin and follistatin was monitored
in real time by a laser confocal microscope and shown to localize
at the sub-nuclear region of HeLa cells. Additional yeast two-
hybrid analysis revealed that domains 2 and 3 of follistatin were
the minimal structure requirement for angiogenin binding. These
ﬁndings provide new clues for further studies on the mechanisms
of angiogenin-induced angiogenesis or cancer cell growth.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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interaction1. Introduction
Angiogenin is a 14-kDa angiogenic protein originally iso-
lated from the conditioned medium of HT-29 human colon
adenocarcinoma cells based solely on its capacity to induce
angiogenesis [1]. It exerts its angiogenic function by activating
endothelial and smooth muscle cells and inducing a number of
cellular activities, including cell migration, invasion, prolifera-
tion, and formation of tubular structures [2,3]. Recently angio-
genin has been reported to translocate into the nucleus of
HeLa cells and PC-3 cells. Down-regulation of angiogenin
expression inhibits the proliferation of both cells [4,5], suggest-
ing a direct function of angiogenin on cancer cells.
However, the molecular mechanisms underlying the func-
tions of angiogenin remain elusive. It is known that angiogenin
binds to actin or to a putative 170 kD protein [2], and activates
ERK1/2 and PKB/Akt in human umbilical vein endothelialAbbreviations: ANG, angiogenin; FS, follistatin; FRET, ﬂuorescence
resonance energy transfer; CFP, cyan ﬂuorescent protein; YFP, yellow
ﬂuorescent protein; Erk, extracellular signal-regulated kinase; JNK/
SAPK, c-Jun N-terminal kinase/stress activated protein kinase; PKB,
protein kinase B; Y2H, yeast two-hybrid
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doi:10.1016/j.febslet.2007.10.059cells [6,7], as well as c-Jun N-terminal kinase/stress activated
protein kinase (JNK/SAPK) in human umbilical artery
smooth muscle cells [3]. Meanwhile, exogenously applied
angiogenin can translocate into the nucleus of target cells
through an unknown mechanism, and enhance rRNA tran-
scription [4,8,9].
Protein interactions are supposed to play important roles in
angiogenin-induced angiogenesis and cancer cell growth, but
until now only a few proteins have been identiﬁed as binding
partners to angiogenin [10–13]. To identify additional media-
tors or modulators of angiogenin activity, we carried out a
yeast two-hybrid screen and identiﬁed follistatin as a potential
angiogenin-interacting protein.
Follistatin has gained recognition as an important mediator
of cell secretion, development, and diﬀerentiation in a number
of tissue and organisms [14,15]. Most of follistatin’s functions
are attributed to its high aﬃnity for some TGF-beta family
members including activin, bone morphogenetic proteins
(BMPs), and myostatin. More recently, ﬁbronectin, one matrix
protein, was identiﬁed as a new partner for follistatin and the
interaction was proved to play a role in the regulation of
human hematopoietic cell adhesiveness [16], indicating that
follistatin is a multifunctional protein and its interacting part-
ners are not restricted to TGF-beta family members. In the
present study, the association of follistatin with angiogenin
was conﬁrmed both in vitro and in vivo. In addition, the bind-
ing domain on follistatin was further explored.2. Materials and methods
2.1. Plasmid construction
The follistatin gene, excluding its signal sequence, was subcloned
into vector pET-28a (Novagen) after PCR ampliﬁcation with primers
FS-pET-For and FS-pET-Rev to produce pET28a-FS.
For ﬂuorescence resonance energy transfer (FRET) analysis, follist-
atin (FS) was ampliﬁed with primers FS-CFP-For and FS-CFP-Rev,
and fused to the cyan ﬂuorescent protein (CFP) sequence by cloning
into the HindIII and BamHI sites of vector pECFP-C1 (Clontech) to
generate pCFP-FS.
The mature follistatin molecule is composed of an N-terminal seg-
ment followed by three cysteine-rich homologous FS domains. To con-
struct follistatin deletion mutants, DNA fragments corresponding to
domain deletions of follistatin (Table 1) were ampliﬁed by PCR from
plasmid pFS288mycHis (kindly provided by Henry T. Keutmann,
Massachusetts General Hospital, Boston) using the primers listed in
Table 2. PCR products were cloned into the pPC86 vectors to produce
fusion proteins with the Gal4 activation domain.
The construction of the plasmids pDBLeu-ANG and pANG-YFP
were described previously [13].blished by Elsevier B.V. All rights reserved.
Table 1
Primer for generation of follistatin mutants
Follistatin mutant Primer set Amino acid
FS1 FS-1-For + FS-1-Rev 64–136
FS2 FS-2-For + FS-2-Rev 137–211
FS3 FS-3-For + FS-3-Rev 212–288
FS12 FS-1-For + FS-2-Rev 64–211
FS23 FS-2-For + FS-3-Rev 137–288
FS13 = FS13-1 FS-1-For + FS-10-Rev 64–136
+FS13-3 FS-30-For + FS-3-Rev +212–288
Fig. 1. Follistatin interacts with angiogenin in yeast cells and in vitro
system. (A) Follistatin was identiﬁed as an angiogenin-binding partner.
Yeast cells were transformed with pPC86 or pPC86-FS along with
pDBLeu or pDBLeu-ANG as indicated. Transformants along with
yeast control strains A–E were subjected to X-gal analysis. The b-
galactosidase-positive colony (blue staining) indicates a positive
interaction inside the cells. (B) Angiogenin was pulled down by
follistatin speciﬁcally. Angiogenin was mixed with recombinant
6 ·His-tagged follistatin and then incubated with Ni2+-NTA-agarose
(lane2). The pull-down products were detected by immunoblotting
with an anti-angiogenin polyclonal antibody. Ni2+-NTA-agarose
incubated with each single protein served as a negative control (lanes
3 and 4). Angiogenin protein was utilized as a running control (lane 1)
in the immunoblotting analysis.
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of all target fragments in the constructs were conﬁrmed by sequencing.
2.2. Yeast two-hybrid analysis
The ProQuest Two-Hybrid System (Gibco) was used to identify
clones that interact with angiogenin from a human heart cDNA
library. Brieﬂy, the bait plasmid pDBLeu-ANG was transformed into
the yeast strain MaV203 together with the cDNA library cloned into
vector pPC86. Yeast clones were ﬁrst selected by growth on selective
medium SC-Leu-Trp-His (lacking leucine, tryptophan, and histidine)
plus 10 mM 3-amino-1,2,4-triazole. Then the grown clones on the
SD-Trp-Leu-His dishes were transferred onto a ﬁlter paper and sub-
jected to b-galactosidase activity testing (X-gal analysis). Yeast control
strains A–E, which represent none interaction, weak interaction, mod-
erately strong interaction, strong interaction, and very strong interac-
tion respectively, were applied to X-gal analysis simultaneously.
Clones showing blue color within 24 h were designated as positive
clones. Plasmids from positive clones were extracted and sequenced.
The corresponding genes were identiﬁed by BLASTn alignment to
the NCBI database.
To map the interaction site of angiogenin in FS by yeast two-hybrid
approach, MaV203 was co-transformed with pDBLeu-ANG and one
of the pPC86 plasmids encoding FS deletion mutants FS1, FS2, FS3,
FS23, FS12, and FS13 (Fig. 4). The interaction was evaluated by the
X-gal analysis. Each experiment was conducted at least three times.
2.3. Pull-down experiment
The protein expression and 6 · [His] pull-down experiment were
conducted as described before [13]. Brieﬂy, pET28a-FS (or pET28a
as a negative control) was transformed into the Escherichia coli strain
BL21 (DE3) and protein expression was induced by isopropyl-1-thio-
b-D-galactopyranoside (IPTG). The bacteria were lysed by sonication,
clariﬁed by centrifugation, and the supernatants were taken to incu-
bate with 10 ll of 50% slurry of Ni2+-agarose (Qiagen). After washing,
angiogenin was added and incubated in the binding buﬀer. After incu-
bation, resins were washed with the binding buﬀer. Bound proteins
were eluted and subjected to Western Blotting with polyclonal anti-
body against angiogenin (Santa Cruz Biotechnology).
2.4. Cell culture and transfection
HeLa cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(Gibco) supplemented with 10% fetal bovine serum (Hyclone) at 37 C
in 5% humidiﬁed CO2. Cells destined for FRET analysis were seeded atTable 2
Sequence of each primer
Primer name Sequence
FS-pET-For GGAATTCGGGAACTGCTGGCT
FS-pET-Rev CCGCTCGAGGTTGCAAGATCC
FS-CFP-For CCCAA GCT TCG GGGAACTG
FS-CFP-Rev CGGGATCCGTTGCAAGATCCG
FS-1-For ACGCGTCGACCGAAACGTGTG
FS-1-Rev ATTTGCGGCCGCTTATTTACA
FS-2-For ACGCGTCGACCAAGACTTGTC
FS-2-Rev ATTTGCGGCCGCTTAGATACA
FS-3-For ACGCGTCGACCAAAGCAAAGT
FS-3-Rev ATTTGCGGCCGCTTAGTTGCA
FS-10-Rev GGAATTCTTTACATCTGCCTT
FS-30-For GGAATTCAAAGCAAAGTCCTGa density of 1 · 105/cm2 on glass cover slips placed in 6-well plates and
incubated for 24 h. Subsequently, transfection was carried out using
Lipofectamine2000 (Invitrogen) as a mediator according to the manu-
facturer’s instruction. Equal amounts of plasmids were utilized in the
double transfection experiment.
2.5. Confocal microscope scanning and ﬂuorescent resonance energy
transfer (FRET) analysis
Twenty-four hours after transfection, HeLa cells were examined
with a 40· oil immersion objective. Confocal microscopic images were
obtained with a Leica confocal imaging spectrophotometer system
(TCS-SP, Heidelburg, Germany). An excitation wavelength of
458 nm and an emission wavelength of 470–500 nm were used for
CFP, and an excitation wavelength of 514 nm and an emission wave-
length of 520–550 nm were used for yellow ﬂuorescent protein (YFP).Restriction enzyme
CC EcoRI
GGAG XhoI
CTGGCTCC HindIII
GAGTG BamHI
AGAAC SalI
TCTGCCTTG NotI
GGGATG SalI
CTTTCCCTC NotI
CCTGTG SalI
AGATCCGGAG NotI
G EcoRI
TG EcoRI
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photobleaching method using the laser-scanning confocal microscopy
was applied [17]. CFP and YFP images were collected repetitively at
a 10 s interval for ﬁve times. After that, YFP was photobleached with
the full power of the 514 nm line laser, and the emission intensities of
CFP and YFP were monitored for an additional ﬁve times. FRET
eﬃciency (FRETE) was calculated as the percentage of the CFP
ﬂuorescence recovery [FRETE = (CFPA  CFPB)/CFPA · 100%],
where CFPA was the CFP intensity after photobleaching and CFPB
was the CFP intensity before photobleaching of YFP. FRETE should
be no more than 0 in the absence of FRET. Otherwise, FRET is con-
sidered to have occurred. Photobleaching data from 10 independent
experiments were subjected to One-way ANOVA analysis. A probabil-
ity level (P value) of less than 0.05 was considered to be statistically sig-
niﬁcant. Data are presented as the means ± S.D.3. Results
3.1. FS interacts with ANG in yeast cells
We have employed the yeast two-hybrid technique to screen
a human heart cDNA library by using angiogenin as the bait
[13]. Out of about 3 · 106 independent transformants, 66 puta-
tive positive colonies were isolated that could grow on histidine
deﬁcient plates and activate the b-galactosidase reporter gene.
DNA sequencing and BLASTn alignment revealed that one
clone coded for human follistatin gene, overlapping with a re-
gion from residue 50 to the C-terminal end (NM_006350,
Fig. 4, FS123). To reconﬁrm the interaction between angioge-
nin and follistatin, yeast cells were co-transformed with pDB-
Leu or pDBLeu-ANG along with pPC86 or pPC86-FS.
Transformants turned blue in X-gal analysis only when angio-Fig. 2. Follistatin colocalizes with angiogenin in the nucleus. HeLa cells were
or ANG-YFP (B) or both (C). The photographs were taken 24 h post-transf
images (left panel) and phase contrast images (right panel) of the cells in the
YFP channel is also shown.genin and follistatin were simultaneously expressed (Fig. 1A),
demonstrating a true interaction between angiogenin and fol-
listatin in yeast.
3.2. FS interacts with ANG in an in vitro system
To corroborate the interaction between follistatin and angio-
genin, we performed a pull-down experiment. Recombinant
6· His-tagged follistatin was expressed and roughly puriﬁed
from the transformed bacterial supernatant by complexation
with Ni2+-NTA-agarose, Angiogenin was added to the mix-
ture, and the ﬁnal Ni2+-agarose bound products were immuno-
blotted with polyclonal antibody against angiogenin.
Angiogenin was detected in pulled-down products only when
6· His-tagged follistatin was present (Fig. 1B), indicating fol-
listatin interacted with angiogenin speciﬁcally in the in vitro
system.
3.3. FS co-localizes with ANG in the nucleus
A presumption that follistatin and agiogenin are functional
partners implies that they would localize to the same cellular
compartment. To detect the localization of the two proteins,
their genes were tagged with CFP and YFP sequences, respec-
tively, and transfected into HeLa cells, either alone or together.
The transfected cells were monitored with a confocal micro-
scope. Data revealed that each single transfection of either
protein showed even distribution of the corresponding protein
in the nucleus (Fig. 2A and B). However, in cells co-expressing
the fusion proteins CFP-FS and ANG-YFP, the distribution
pattern was altered: both still appeared in the nucleus, but withtransiently transfected with expression plasmids encoding CFP-FS (A)
ection at a magniﬁcation of 400·. Each picture shows the ﬂuorescence
same ﬁeld. For co-transfection group, the merged image of CFP and
Fig. 3. FRET analysis demonstrates that angiogenin interacts with follistatin in HeLa cell nucleus. HeLa cells transfected with (A) CFP-FS/ANG-
YFP, (C) CFP-FS/YFP, or (E) CFP/ANG-YFP were subjected to FRET analysis. CFP (a) and YFP (c) images before photobleaching and CFP (b)
and YFP (d) images after photobleaching are shown. The bleached cell is indicated with a white arrow. The changes of CFP and YFP emission
intensities in the cell before and after photobleaching were shown in B, D, and F. The vertical arrow indicates the start-time point of photobleaching.
The FRET eﬃciency (FRETE) was calculated as the percentage of the CFP ﬂuorescence recovery (G). *One-way ANOVA, P < 0.01 compared to
CFP/ANG-YFP; P < 0.01 compared to CFP-FS/YFP.
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tion at particular foci within the nucleus (Fig. 2C).
3.4. FRET occurs between follistatin and angiogenin in the
nucleus of HeLa cells
Having observed the co-localization of CFP-FS with ANG-
YFP in a sub-nuclear compartment, we further investigated
their interaction using FRET methodology. Theoretically, ifan interaction between CFP and YFP tagged proteins bring
them in close proximity, photonic energy from excited CFP
molecules could be directly transferred to YFP molecules. If
the presumed energy acceptor YFP is photobleached, emission
intensity of the donor CFP would increase because YFP loses
its ability to accept transferred energy from the donor. In
fact, we observed an increase of CFP emission after YFP
photobleaching in CFP-FS/ANG-YFP group (Fig. 3A and
Fig. 4. Mapping of the ANG-interacting domain of FS. (A) Schematic
illustration of follistatin and its truncated fragments and their binding
with angiogenin. The ‘‘+’’ stands for positive interaction in X-gal
analysis while ‘‘’’ for negative interaction. (B) DNA fragments
encoding the indicated follistatin domains were subcloned into the
pPC86 vector. Each of these follistatin mutant plasmids was cotrans-
formed into yeast with pDBLeu-ANG. Transformants along with
yeast control strains A–E were subjected to X-gal analysis. The b-
galactosidase-positive colony (blue staining) indicates a positive
interaction inside the cells.
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ANG-YFP in HeLa nucleus. No increase was observed in
the two control groups CFP-FS/YFP and CFP/ANG-YFP
(Fig. 3C and D, E and F). For each group, 10 independent
cells were selected for repetition, and they showed consistent
results. The FRETE of the two control groups were
3.39 ± 3.05% and 3.95 ± 1.88%, respectively, while the
FRETE of CFP-FS/ANG-YFP was 22.69 ± 6.05% (Fig. 3G).
These results lend further evidence to demonstrate that FS
interacts with ANG in the nucleus.
3.5. FS domains 2 and 3 are necessary for angiogenin binding
The full follistatin molecule is composed of a signal peptide,
an N-terminal segment and three FS domains (Fig. 4A, FS).
The clone we isolated in the yeast two-hybrid (Y2H) screening
contains three FS domains and part of the N terminal domain
(Fig. 4A, FS123). To determine the speciﬁc structural motif(s)
that mediates its binding to angiogenin, we constructed a seri-
ous of truncated fragments of FS in vector pPC86 (Fig. 4A)
and evaluated their interactions with angiogenin in the yeast
two-hybrid system. Data showed that each individual follista-
tin domain did not interact with angiogenin (Fig. 4B). We then
tested the binding abilities of three truncated constructs, FS12,
FS23 and FS13, which deleted follistatin domain 3, follistatin
domain 1 and follistatin domain 2, respectively. The data dem-
onstrated that only FS23 has angiogenin-binding capacity(Fig. 4B), indicating that FS domains 2 and 3 are both neces-
sary and suﬃcient for angiogenin interacting.4. Discussion
To obtain greater insight into potential mechanistic partners
by which angiogenin exerts its biological functions, we per-
formed yeast two-hybrid screening using angiogenin as the
bait. The analysis identiﬁed follistatin, a secreted regulatory
protein [18], as a potential molecular partner which interacts
with angiogenin. Here, we summarize all the lines of evidence,
both in vitro and in vivo, which demonstrate a real interaction
between angiogenin and follistatin.
By using ﬂuorescent proteins as indicators, we observed the
nuclear localization of YFP-tagged angiogenin. This is consis-
tent with the previous ﬁndings that angiogenin translocates
into the nucleus [6,8]. Up to now, follistatin was recognized
as a secretory protein [18]. Our results show obvious nuclear
localization of CFP-tagged mature follistatin, indicating a role
of follistatin in the nucleus. Co-transfection of follistatin and
angiogenin genes revealed a punctate distribution in the sub-
nuclear region. FRET analysis of the co-expressed proteins
showed that both proteins are within close proximity in these
focal points. Together these results suggest that follistatin
and angiogenin interact in the nucleus. But the novelty of this
conclusion needs further conﬁrmatory studies on the complex
formed by angiogenin and follistatin under physiological or
pathological conditions and their possible relationship with
sub-nuclear organelles such as ‘speckles’ or Cajal bodies [19].
Given the traditional view of follistatin as a secreted protein,
we must examine carefully the possibility that the two proteins
interact extracellularly as well. Follistatin has been reported to
inhibit the eﬀects of activin by complexation with it, which in
turn blocks activin’s binding to its receptor [20] and/or acceler-
ates their endocytosis and degradation [21]. Our pull-down
experiment demonstrated that the interaction between angio-
genin and follistatin is direct and independent of the third part-
ner. So it is of interest to explore if the binding could inﬂuence
the interaction between angiogenin and its extracelluar recep-
tors, and/or the internalization of angiogenin.
The mature follistatin molecule is comprised of three
domains, each containing 10 cysteines, preceded by an
N-terminal segment. The three FS domains share about 50%
primary sequence homology [22]. Our experiments showed
that FS domains 2 and 3 are both required for angiogenin
binding – deletion of either abolished its interaction with
angiogenin. The ﬁrst and second FS domains (FS12) have been
shown to be minimal requisites for activin binding with a key
residue in domain 2 [23]. All these results imply a probable key
role of FS domain 2 in follistatin’s regulatory activity on other
growth factors’ functions.
In summary, we have identiﬁed follistatin as a novel binding
partner for angiognein and detected their interaction in the
sub-nuclear region. These results provide new insight into
the mechanisms underlying the angiogenic and tumorigenic ef-
fects of angiogenin.
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